Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus
Individuals with human immunodeficiency virus (HIV) infection are prone to developing persistent and unremitting anogenital warts (AGWs). To address this health condition, immunotherapy using tuberculin purified protein derivative (PPD) has been proven to be a promising novel and safe treatment for...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-01-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/dr/article/view/9754 |
| _version_ | 1797338541499351040 |
|---|---|
| author | Pati Aji Achdiat Stephanie Widjaja Oki Suwarsa Reiva Farah Dwiyana Reti Hindritiani Endang Sutedja Hendra Gunawan Hermin Aminah Usman Fathia Rianty Retno Hesty Maharani |
| author_facet | Pati Aji Achdiat Stephanie Widjaja Oki Suwarsa Reiva Farah Dwiyana Reti Hindritiani Endang Sutedja Hendra Gunawan Hermin Aminah Usman Fathia Rianty Retno Hesty Maharani |
| author_sort | Pati Aji Achdiat |
| collection | DOAJ |
| description |
Individuals with human immunodeficiency virus (HIV) infection are prone to developing persistent and unremitting anogenital warts (AGWs). To address this health condition, immunotherapy using tuberculin purified protein derivative (PPD) has been proven to be a promising novel and safe treatment for AGWs in HIV patients. Therefore, this study involved a case of a 21-year-old man with stage I HIV infection, possessing CD4 counts 548 cells/uL and routinely receiving HIV antiretroviral. Patients presented with a condyloma acuminata type AGWs, supported by histopathological results, and tested positive for Human papillomavirus type 11. The treatment approach involved administering 15 tuberculin units of PPD weekly to the largest lesion for 5 weeks. The lesion started to respond two weeks following the first injection and showed a 50% decrease in size after five weeks. There was pain on the site of injection and sub-febrile for a short period. In conclusion, tuberculin PPD is safe and has the potential for the treatment of AGWs in HIV-positive patients for further development.
|
| first_indexed | 2024-03-08T09:32:46Z |
| format | Article |
| id | doaj.art-4a4d2380ba6342898b7836ec58a95e3e |
| institution | Directory Open Access Journal |
| issn | 2036-7392 2036-7406 |
| language | English |
| last_indexed | 2024-03-08T09:32:46Z |
| publishDate | 2024-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj.art-4a4d2380ba6342898b7836ec58a95e3e2024-01-30T18:58:44ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062024-01-0110.4081/dr.2024.9754Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virusPati Aji Achdiat0Stephanie Widjaja1Oki Suwarsa2Reiva Farah Dwiyana3Reti Hindritiani4Endang Sutedja5Hendra Gunawan6Hermin Aminah Usman7Fathia Rianty8Retno Hesty Maharani9Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung; Doctoral Study Program, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, BandungDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung Individuals with human immunodeficiency virus (HIV) infection are prone to developing persistent and unremitting anogenital warts (AGWs). To address this health condition, immunotherapy using tuberculin purified protein derivative (PPD) has been proven to be a promising novel and safe treatment for AGWs in HIV patients. Therefore, this study involved a case of a 21-year-old man with stage I HIV infection, possessing CD4 counts 548 cells/uL and routinely receiving HIV antiretroviral. Patients presented with a condyloma acuminata type AGWs, supported by histopathological results, and tested positive for Human papillomavirus type 11. The treatment approach involved administering 15 tuberculin units of PPD weekly to the largest lesion for 5 weeks. The lesion started to respond two weeks following the first injection and showed a 50% decrease in size after five weeks. There was pain on the site of injection and sub-febrile for a short period. In conclusion, tuberculin PPD is safe and has the potential for the treatment of AGWs in HIV-positive patients for further development. https://www.pagepress.org/journals/index.php/dr/article/view/9754Anogenital wartspurified protein derivativeimmunotherapyhuman papillomavirushuman immunodeficiency virus |
| spellingShingle | Pati Aji Achdiat Stephanie Widjaja Oki Suwarsa Reiva Farah Dwiyana Reti Hindritiani Endang Sutedja Hendra Gunawan Hermin Aminah Usman Fathia Rianty Retno Hesty Maharani Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus Dermatology Reports Anogenital warts purified protein derivative immunotherapy human papillomavirus human immunodeficiency virus |
| title | Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus |
| title_full | Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus |
| title_fullStr | Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus |
| title_full_unstemmed | Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus |
| title_short | Effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus |
| title_sort | effectiveness and safety of tuberculin purified protein derivative for the treatment of anogenital warts in patients with human immunodeficiency virus |
| topic | Anogenital warts purified protein derivative immunotherapy human papillomavirus human immunodeficiency virus |
| url | https://www.pagepress.org/journals/index.php/dr/article/view/9754 |
| work_keys_str_mv | AT patiajiachdiat effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT stephaniewidjaja effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT okisuwarsa effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT reivafarahdwiyana effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT retihindritiani effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT endangsutedja effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT hendragunawan effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT herminaminahusman effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT fathiarianty effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus AT retnohestymaharani effectivenessandsafetyoftuberculinpurifiedproteinderivativeforthetreatmentofanogenitalwartsinpatientswithhumanimmunodeficiencyvirus |